hydrochlorothiazide has been researched along with Carcinoma, Basal Cell in 19 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 2018, the Pharmacological Risk Assessment Committee alerted to a potential relationship between accumulated hydrochlorothiazide dosage and the risk of non-melanoma skin cancer." | 8.02 | Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. ( Lecaros-Astorga, DA; Martin-Arias, LH; Molina-Guarneros, JA; Rodríguez-Jiménez, P; Sainz-Gil, M, 2021) |
| "In 2018, the Pharmacological Risk Assessment Committee alerted to a potential relationship between accumulated hydrochlorothiazide dosage and the risk of non-melanoma skin cancer." | 4.02 | Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. ( Lecaros-Astorga, DA; Martin-Arias, LH; Molina-Guarneros, JA; Rodríguez-Jiménez, P; Sainz-Gil, M, 2021) |
| "Patients within the lip cancer and oral cancer groups were accepted with a history of non-melanoma skin cancer (NMSC)." | 2.82 | Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population? ( Carney, K; Cousins, M, 2022) |
| "Non-melanoma skin cancer is the most prevalent malignancy in fair-skinned people and its incidence is increasing." | 2.66 | Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature. ( Borges-Costa, J; Garrido, PM, 2020) |
| " These results do not modify the benefit/risk ratio but should lead to propose preventive mesures: identification of high risk population, avoidance of this drug if possible in immunocompromised patients or with previous skin cancer, regular skin examination in case of long term use of hydrochlorothiazide." | 2.61 | [Hydrochlorothiazide use and risk of skin cancers: A systematic review]. ( Becquart, O; Bourrain, JL; Du-Thanh, A; Duflos, C; Guillot, B, 2019) |
| "Hydrochlorothiazide and skin cancer Hydrochlorothiazide is a frequently prescribed diuretic with known photosensitizing properties." | 2.61 | [Hydrochlorothiazide and skin cancer]. ( Olde Engberink, RHG; van den Born, BH; van der Hoeven, NV; Zwinderman, AH, 2019) |
| " The aim of this study was to investigate the association between hydrochlorothiazide use and incidence of skin cancer in a cohort of unselected Caucasian adults, taking dosing into account." | 1.91 | Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study. ( Bos, J; De Bock, GH; De Vos, S; Greven, N; Haisma, MS; Hak, E; Horváth, B; Logendran, M; Rácz, E; van der Vegt, B, 2023) |
| "BCC recurrences were statistically significant with age, longer follow-up, and positive margins after excision in HCTZ users (p = 0." | 1.91 | The effect of hydrochlorothiazide on the recurrence of nonmelanoma skin cancer: a 7-year retrospective study comprising 300 patients. ( Akıncı, K; Albayati, A; Özkan, B; Savran, S; Uysal, AÇ; Uysal, Pİ, 2023) |
| " We did not find a dose-response relationship between HCTZ use and NMSC." | 1.72 | Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide? ( Cione, E; De Sarro, G; Gallelli, L; Gerace, A; Guerra, A; Leuzzi, G; Longo, L; Luciani, F; Muraca, L; Natale, V; Scaramuzzino, A; Scuteri, A; Siniscalchi, A; Vasapollo, P; Vasta, G; Zampogna, S, 2022) |
| "We recommend regular skin cancer screening, moderate ordination of photosensitizing medication, but above all comprehensive clarification of possible risks." | 1.72 | The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. ( Druchkiv, V; Garbe, C; Hagenström, K; Mehlan, J; Schuettauf, F; Spitzer, MS; Ueberschaar, J, 2022) |
| "Hydrochlorothiazide (HCTZ) use has been linked to skin cancer in northern European countries." | 1.62 | Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain. ( Díaz, Y; Duarte-Salles, T; Huerta, C; León-Muñoz, LM; Llorente, A; Montero-Corominas, D; Pottegård, A; Puente, D, 2021) |
| "Hydrochlorothiazide exposure was associated with an increased risk of SCC, BCC and lip cancer that is not explained following adjustment for smoking and BMI." | 1.56 | Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. ( Kurz, X; Morales, DR; Pacurariu, A; Slattery, J, 2020) |
| " We found clear dose-response relationships between hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1." | 1.48 | Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. ( Friis, S; Gaist, D; Hölmich, LR; Pedersen, SA; Pottegård, A; Schmidt, SAJ, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 15 (78.95) | 2.80 |
| Authors | Studies |
|---|---|
| Tiba, APL | 1 |
| Cury-Martins, J | 1 |
| Miyashiro, DR | 1 |
| Sanches, JA | 1 |
| Gallelli, L | 1 |
| Cione, E | 1 |
| Siniscalchi, A | 1 |
| Vasta, G | 1 |
| Guerra, A | 1 |
| Scaramuzzino, A | 1 |
| Longo, L | 1 |
| Muraca, L | 1 |
| De Sarro, G | 1 |
| Leuzzi, G | 1 |
| Gerace, A | 1 |
| Scuteri, A | 1 |
| Vasapollo, P | 1 |
| Natale, V | 1 |
| Zampogna, S | 1 |
| Luciani, F | 1 |
| Mehlan, J | 1 |
| Ueberschaar, J | 1 |
| Hagenström, K | 1 |
| Garbe, C | 1 |
| Spitzer, MS | 1 |
| Druchkiv, V | 1 |
| Schuettauf, F | 1 |
| Carney, K | 1 |
| Cousins, M | 1 |
| Haisma, MS | 1 |
| Greven, N | 1 |
| Logendran, M | 1 |
| Bos, J | 1 |
| van der Vegt, B | 1 |
| Horváth, B | 1 |
| De Vos, S | 1 |
| De Bock, GH | 1 |
| Hak, E | 1 |
| Rácz, E | 1 |
| Özkan, B | 1 |
| Savran, S | 1 |
| Akıncı, K | 1 |
| Albayati, A | 1 |
| Uysal, Pİ | 1 |
| Uysal, AÇ | 1 |
| Morales, DR | 1 |
| Pacurariu, A | 1 |
| Slattery, J | 1 |
| Kurz, X | 1 |
| Garrido, PM | 1 |
| Borges-Costa, J | 1 |
| Adalsteinsson, JA | 1 |
| Muzumdar, S | 1 |
| Waldman, R | 1 |
| Hu, C | 1 |
| Wu, R | 1 |
| Ratner, D | 1 |
| Ungar, J | 1 |
| Silverberg, JI | 1 |
| Olafsdottir, GH | 1 |
| Kristjansson, AK | 1 |
| Tryggvadottir, L | 1 |
| Jonasson, JG | 1 |
| Letellier, T | 1 |
| Leborgne, F | 1 |
| Kerleau, C | 1 |
| Gaultier, A | 1 |
| Dantal, J | 1 |
| Ville, S | 1 |
| Lecaros-Astorga, DA | 1 |
| Molina-Guarneros, JA | 1 |
| Rodríguez-Jiménez, P | 1 |
| Martin-Arias, LH | 1 |
| Sainz-Gil, M | 1 |
| Eworuke, E | 1 |
| Haug, N | 1 |
| Bradley, M | 1 |
| Cosgrove, A | 1 |
| Zhang, T | 1 |
| Dee, EC | 1 |
| Adimadhyam, S | 1 |
| Petrone, A | 1 |
| Lee, H | 1 |
| Woodworth, T | 1 |
| Toh, S | 1 |
| León-Muñoz, LM | 1 |
| Duarte-Salles, T | 1 |
| Llorente, A | 1 |
| Díaz, Y | 1 |
| Puente, D | 1 |
| Pottegård, A | 2 |
| Montero-Corominas, D | 1 |
| Huerta, C | 1 |
| Hollestein, LM | 1 |
| Arnspang Pedersen, S | 1 |
| Pedersen, SA | 1 |
| Gaist, D | 1 |
| Schmidt, SAJ | 1 |
| Hölmich, LR | 1 |
| Friis, S | 1 |
| Becquart, O | 1 |
| Guillot, B | 1 |
| Bourrain, JL | 1 |
| Duflos, C | 1 |
| Du-Thanh, A | 1 |
| Olde Engberink, RHG | 1 |
| van der Hoeven, NV | 1 |
| Zwinderman, AH | 1 |
| van den Born, BH | 1 |
| Cognetta, AB | 1 |
| Wolfe, CM | 1 |
| Heinrichs, E | 1 |
5 reviews available for hydrochlorothiazide and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population?
Topics: Adult; Carcinoma, Basal Cell; Humans; Hydrochlorothiazide; Incidence; Lip Neoplasms; Skin Neoplasms; | 2022 |
Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinoma, Basal Cell; Humans; Hydrochlorothiazide | 2020 |
[Hydrochlorothiazide use and risk of skin cancers: A systematic review].
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazide; Melanoma; Risk Assessm | 2019 |
[Hydrochlorothiazide and skin cancer].
Topics: Blood Pressure; Carcinoma, Basal Cell; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Skin Ne | 2019 |
Hydrochlorothiazide Use and Skin Cancer: A Mohs Surgeon's Concern.
Topics: Antihypertensive Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazid | 2016 |
14 other studies available for hydrochlorothiazide and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population.
Topics: Brazil; Carcinoma, Basal Cell; Case-Control Studies; Humans; Hydrochlorothiazide; Pilot Projects; Sk | 2022 |
Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide?
Topics: Antihypertensive Agents; Carcinoma, Basal Cell; Female; Humans; Hydrochlorothiazide; Male; Retrospec | 2022 |
The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region.
Topics: Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Basal Cell; Female; Humans; Hydrochlorothiazide | 2022 |
Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study.
Topics: Adult; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cohort Studies; Humans; Hydrochlorothiazide; | 2023 |
The effect of hydrochlorothiazide on the recurrence of nonmelanoma skin cancer: a 7-year retrospective study comprising 300 patients.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazide; Recurrence; Retr | 2023 |
Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies.
Topics: Adult; Carcinoma, Basal Cell; Case-Control Studies; Humans; Hydrochlorothiazide; Incidence; Lip Neop | 2020 |
Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, | 2021 |
Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients.
Topics: Adult; Age Factors; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Databases, Factual; Diuretics; | 2020 |
Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study.
Topics: Carcinoma, Basal Cell; Humans; Hydrochlorothiazide; Melanoma; Risk Factors; Skin Neoplasms; Spain | 2021 |
In Brief: Hydrochlorothiazide and skin cancer.
Topics: Antihypertensive Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Drug Labeling; Humans; Hyd | 2020 |
Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carcino | 2021 |
Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain.
Topics: Carcinoma, Basal Cell; Case-Control Studies; Humans; Hydrochlorothiazide; Skin Neoplasms; Spain | 2021 |
Increased cutaneous squamous cell carcinoma risk with hydrochlorothiazide use: is there a safe alternative?
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Case-Control Studies; Humans; Hydrochlorothiazide; | 2021 |
Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; C | 2018 |